Related Experiment Videos
Abstract:
A 14-year-old boy survived for 7 years after the initial diagnosis and treatment of acute lymphocytic leukemia. Neurologic deterioration occured repeatedly throughout his complicated clinical course but it was most severe and only partially reversible following orally administered pyrimethamine. The neuropathologic lesions were distinctive and included a diffuse reactive astrocytosis, axonal degeneration, status spongiosis, circumscribed foci of demyelination and coagulative necrosis, and mural thickening with luminal narrowing of microcirculatory vessels. This collection of findings represents the leukoencephalopathy of childhood leukemia that we and others believe results in large part from the combined effects of cranial irradiation and chemotherapy. The role of folic acid antagonists, namely methotrexate and pyrimethamine, are particularly noteworthy in this regard.
Insights
This study details a rare case of childhood leukemia survivor experiencing severe neurological decline due to treatment side effects. The findings highlight leukoencephalopathy from cranial irradiation and chemotherapy, particularly folic acid antagonists.
Area of Science:
- Neuropathology
- Pediatric Oncology
- Neuro-oncology
Background:
- Acute lymphocytic leukemia (ALL) is a common childhood cancer.
- Long-term survivors of ALL may face significant treatment-related toxicities.
- Understanding treatment complications is crucial for improving long-term outcomes.
Observation:
- A 14-year-old boy with ALL experienced recurrent neurologic deterioration over 7 years.
- Severe, partially reversible neurological decline occurred after pyrimethamine treatment.
- Distinct neuropathologic lesions were observed, including astrocytosis, axonal degeneration, demyelination, and vascular changes.
Findings:
- The observed neuropathology is consistent with leukoencephalopathy in childhood leukemia survivors.
- This condition is believed to result from combined effects of cranial irradiation and chemotherapy.
- Folic acid antagonists, such as methotrexate and pyrimethamine, play a notable role.
Implications:
- Highlights the potential for severe neurotoxicity from standard leukemia treatments.
- Emphasizes the need for careful monitoring of neurologic function in long-term survivors.
- Suggests a need to re-evaluate the use and monitoring of specific chemotherapeutic agents and radiation protocols.